MHRA International Reliance: What Canadian Device Makers Gain

Canadian medical device makers spend years, and often a great deal of money, earning a Health Canada licence and certifying a quality management system to ISO 13485. Until now, that work has not counted for much when a company wanted to sell the same device in Great Britain. That is beginning to change. In May 2026 the United Kingdom's medicines and devices regulator published draft rules that would let devices already approved in Canada reach the Great Britain market through a new international reliance route, without repeating a full conformity assessment.

For a Canadian manufacturer, this is a strategic opening rather than an immediate one. The rules are still in draft, the timelines run into 2027 and 2028, and the detail will change before anything becomes law. But the direction is clear, and the companies that prepare their technical documentation and quality systems now will move fastest when the route opens. This guide explains what the MHRA international reliance route is, why Canada's place in it matters, how the proposed routes are structured, and the practical steps a Canadian device maker should take today.

Executive Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has published the draft Medical Devices (Amendment) Regulations 2026. Among the reforms is an international reliance scheme that names Australia, Canada and the United States as comparable regulator countries. Devices authorised by these regulators would be able to reach the Great Britain market through a reliance-based route, subject to conditions, rather than a full separate UK assessment. Canada is on the list because Health Canada is recognised as a trusted regulator, which means a Canadian Medical Device Licence and a certified quality management system become genuine assets for UK market access.

What Is the MHRA International Reliance Route?

The MHRA international reliance route is a proposed pathway that would let a medical device already authorised by a trusted overseas regulator be placed on the Great Britain market without repeating the full UK conformity assessment. It matters because it reduces duplicate testing, review and cost for manufacturers that have already cleared a rigorous regulator. Companies should treat it as a market-access opportunity to plan for, and should make sure their existing approval and quality documentation are complete and current. For compliance, it changes the question from whether you can afford a second full assessment to whether you can package your existing evidence in the form the UK will accept.

The concept sits inside the draft Medical Devices (Amendment) Regulations 2026, which the MHRA notified to the World Trade Organization on 8 May 2026. The MHRA first set out its policy intent for international reliance in May 2024, with the stated aim of improving access to safe, quality-assured devices while avoiding duplicate assessments where it is safe to do so. Reliance is one part of a wider reform package that also revises device and in vitro diagnostic classification, re-anchors the UK essential requirements, extends technical documentation retention, and introduces mandatory unique device identifiers.

Why It Matters for Canadian Device Makers

It matters because Canada is named as a comparable regulator country, alongside Australia and the United States. A device that already holds a Canadian Medical Device Licence, backed by a certified quality management system, would be a candidate for the reliance route rather than a full UK assessment. That turns work Canadian makers have already done into a market-access asset. What to do is straightforward in principle: keep your Health Canada authorisation current, keep your ISO 13485 certification live, and keep your technical file in a state you could hand to a reviewer.

Health Canada's inclusion is not an accident. The UK selected regulators whose systems it considers rigorous and whose decisions it is prepared to rely on. Canadian device makers already meet many of the underlying expectations: a licensed device under the Medical Devices Regulations (SOR/98-282) carries a safety and effectiveness evidence base, and Health Canada requires an ISO 13485 quality system certified under the Medical Device Single Audit Program (MDSAP) for most device classes. Those two things, a current licence and a certified quality system, are close to the core of what the UK route is expected to ask for.

How the Reliance Routes Are Proposed to Work

As proposed in the draft, international reliance would operate through risk-based routes. Lower-risk devices would follow a lighter registration path, while higher-risk devices would need a certificate issued through a UK approved body before they could be placed on the market. The exact conditions sit in the draft and will be refined through consultation, so the structure below is the proposed shape rather than settled law. The practical message is that the higher a device's risk class, the more UK oversight the route will still require.

A recurring feature across analysis of the draft is a Certificate of International Reliance. For eligible devices, this certificate would provide a stand-alone route to the Great Britain market without the need for UKCA marking. In other words, reliance is designed to be a route in its own right, not a bolt-on to the existing UK conformity assessment.

Read that table as a planning aid, not a rulebook. The MHRA has said the routes rely on the approvals or certificates issued by the comparable regulators subject to certain conditions, and the final route names, thresholds and evidence requirements will be set in the statutory instrument that follows the consultation.

What the Route Does Not Cover

The international reliance route is limited to devices authorised in Canada, the United States and Australia. The European Union is not part of it. That is a deliberate choice: the draft does not make CE marking a stand-alone route to the Great Britain market. CE-marked devices are being handled through a separate MHRA process on the indefinite recognition of CE-marked devices, whose consultation closed in April 2026. For a Canadian maker, the takeaway is simple: your route into Great Britain is your Canadian approval, not a European one.

It is also worth being clear about what reliance is not. It is not automatic. A named comparable regulator does not mean a Canadian licence flips into a UK authorisation on its own. The manufacturer still has to apply, meet the route's conditions, appoint a UK Responsible Person, and register the device. Reliance reduces duplicate assessment; it does not remove UK obligations such as post-market surveillance, vigilance reporting and traceability.

Timeline: When Canadian Makers Can Rely On This

Not yet, and not for a while. The draft was published in May 2026 and the MHRA's stakeholder impact survey closed on 19 June 2026. Because draft legislation must sit with the World Trade Organization for a comment period before it is laid in Parliament, and because the survey feeds a formal impact assessment, the detail can still shift. Current expectations point to adoption of the core reforms toward the end of 2026, entry into force during 2027, and the international reliance pathway following later, around 2028. Treat every date as a moving target until the statutory instrument is made.

A transitional point matters here too. CE-marked devices remain accepted in Great Britain under existing transitional arrangements until June 2028 or June 2030, depending on the device. So while the reliance route is being built, the current routes to the GB market stay open. Canadian makers do not need to pause UK plans; they need to prepare for a route that will make those plans cheaper.

From Canadian Licence to UK Market: A Worked Example

Consider a Toronto company that holds a Class II Canadian Medical Device Licence for a wound-care product and an ISO 13485 certificate maintained under MDSAP. Under the current UK regime, selling in Great Britain means a separate UKCA conformity assessment, which duplicates much of the evidence the company already generated for Health Canada. Under the proposed reliance route, that same Canadian approval plus the certified quality system would become the basis for a lighter UK path, with the technical file and post-market data doing double duty. The company's advantage is not luck. It is that its documentation was already inspection-ready.

The common failure we see in gap assessments is the opposite case. A firm lets a nonconformity from its last MDSAP audit sit open, or its risk-management file lags behind design changes, or its clinical evidence summary is scattered across departments. None of that blocks a Canadian licence renewal on its own, but it slows any reliance application and invites questions from a UK approved body. A short corrective and preventive action (CAPA) exercise now, closing audit findings and consolidating the technical file, is far cheaper than a rushed remediation once the route opens and buyers start asking for UK availability.

How to Prepare Now: A Readiness Checklist

The best preparation is boring and durable: keep the evidence a reliance route will ask for in good order, so you can move when it opens. Use the checklist below as a starting gap assessment.

• Confirm your Canadian Medical Device Licence is current, and that the licensed device matches what you intend to sell in Great Britain.
• Keep ISO 13485 certification live, ideally under MDSAP, and close any open nonconformities from your last audit.
• Assemble a technical file a reviewer could read on its own: intended purpose, classification rationale, risk management, clinical evidence and post-market data.
• Map your device to its likely UK risk class, since the route's requirements scale with risk.
• Identify and appoint a UK Responsible Person, and confirm how UK registration will be handled.
• Build a post-market surveillance and vigilance plan that meets UK expectations, not only Canadian ones.
• Track the MHRA's final statutory instrument and any guidance on the Certificate of International Reliance.
• Run a documentation gap assessment against the draft essential requirements so remediation starts before, not after, the route opens.

Common Mistakes Canadian Makers Make

• Assuming reliance is automatic. A named comparable regulator still requires an application, conditions and UK registration.
• Waiting for the final rules before touching the technical file. The evidence takes months to assemble; the rules will not.
• Confusing the reliance route with CE-mark recognition. They are separate tracks, and the EU is not part of reliance.
• Letting ISO 13485 or the Canadian licence lapse during a quiet period, which removes the very basis for reliance.
• Ignoring UK post-market duties. Reliance eases market entry, not ongoing vigilance, traceability and reporting.
• Treating a 2028 pathway as a 2028 problem. Buyers, distributors and approved-body capacity will move earlier.

Frequently Asked Questions

Does the UK now recognise Health Canada medical device licences?

Not yet. The draft Medical Devices (Amendment) Regulations 2026 name Canada as a comparable regulator country and propose an international reliance route that would use Canadian approvals. It is a proposal published in May 2026, not law. Until the statutory instrument is made and the route is operational, a Canadian licence does not by itself give access to the Great Britain market.

Which regulators count as comparable under the UK route?

The MHRA has confirmed three comparable regulator countries: Australia, Canada and the United States. The European Union is not included in the international reliance route, and CE-mark recognition is being addressed through a separate MHRA process.

Will a Canadian device still need a UK approved body?

It depends on risk. As proposed, the lowest-risk eligible devices would follow a lighter registration path, while moderate and higher-risk devices would need a Certificate of International Reliance issued through a UK approved body. The final thresholds will be set in the statutory instrument.

When is the international reliance route expected to be available?

Current expectations point to the core reforms being adopted toward the end of 2026, entering into force in 2027, with the international reliance pathway following later, around 2028. These dates are expectations for draft legislation and can change.

Do we still need ISO 13485 for the reliance route?

A certified quality management system is central to eligibility. Canadian makers who hold ISO 13485, ideally under MDSAP, already meet much of that expectation. Keeping the certification live and audit-ready is one of the most valuable preparation steps.

Does reliance remove our UK post-market obligations?

No. Reliance is designed to reduce duplicate pre-market assessment. It does not remove UK obligations such as appointing a UK Responsible Person, registering the device, and meeting post-market surveillance, vigilance and traceability requirements.

How MFLRC Can Help

MFLRC helps Canadian device makers turn existing approvals into international market access. Our team runs technical documentation gap assessments against UK and EU essential requirements, prepares and strengthens ISO 13485 quality management systems, and supports MDSAP readiness so your certification holds up under audit. We advise on device classification, build post-market surveillance and vigilance procedures, and help you structure the evidence a reliance route will expect. For companies weighing several markets at once, we map the fastest, lowest-cost path across Canada, the United States, the EU and the UK.

Conclusion

The UK's draft 2026 device rules put Canada on a short list of trusted regulators and propose a route that would let Canadian-approved devices reach the Great Britain market without a full second assessment. It is not law yet, and the timelines run into 2027 and 2028. But the reform rewards preparation. Canadian makers who keep their licences current, their quality systems audit-ready, and their technical files complete will be the ones that move first when the route opens. The work you have already done for Health Canada is about to count for more.

Sources and References

• MHRA, MHRA announces a proposed framework for international recognition of medical devices (GOV.UK).
• MHRA, Statement of policy intent: international recognition of medical devices (GOV.UK).
• MHRA, Response to international reliance, UKCA marking and in vitro diagnostic devices consultation proposal (GOV.UK).
• Health Canada, Medical devices (Canada.ca).
• ISO 13485:2016, Medical devices, Quality management systems, Requirements for regulatory purposes (ISO).